No Data
No Data
Merck Keytruda With Eisai's Lenvima Succeeds in Late-stage Trial for Liver Cancer
SEED Therapeutics Appoints Eisai Co., Ltd.'s Dr. Yoshiharu Mizui to Board of Directors
Sumitomo Chemical, NEC, etc. (additional) Rating
Upgrade - bullish code | Stock name | Securities company | Previous | After the change | ------ | -------------- | ------------- | -------------- | -------------- | <4043> | Tokuyama | Mizuho | "Hold" | "Buy" | <4208> | UBE | Morgan S | "Equal weight" | "Overweight" | <7
ADR Japanese stock ranking - Advantest and others are almost all rising, Chicago is 825 yen higher than Osaka at 36,595 yen.
ADR (American Depositary Receipt) of Japanese stocks, compared to the Tokyo Stock Exchange (at an exchange rate of 1 dollar = 142.33 yen), Advantest <6857>, Softbank Group <9984>, Japan Post <6178>, Disco <6146>, Tokyo Electron <8035>, Renesas <6723>, Hitachi <6501> and other stocks rose, almost across the board. Chicago Nikkei 225 futures settlement price closed 825 yen higher than Osaka day trade, at 36,595 yen. The U.S. stock market is rising. The Dow Jones Industrial Average is up 124.75 points to 40,861.
The tumor shrinking effect of target protein degrading inducer E7820 has been confirmed in J-PDX (Japanese patient-derived xenograft) models, and physician-led clinical trials have been initiated.
A cross-cutting evaluation of the cancer species-specific protein degradation inducer E7820 from Eisai Co., Ltd., as announced by the National Cancer Center, National Research and Development Agency, on September 12, 2024. It was conducted using patient-derived tumor tissue transplantation (PDX) models (pancreatic cancer, biliary tract cancer, stomach cancer, uterine body cancer) transplanted into immunodeficient mice. In the overall evaluation, tumor shrinkage was observed in 38.1%, 58.3%, and 55.6% of cases for all tumors, biliary tract cancer, and uterine body cancer, respectively.
The yen's appreciation has become a burden, and it has been a month since it reached the 35,000 yen level.
The Nikkei average continued to decline for 7 business days. It closed at 35,619.77 yen, down 539.39 yen (volume approximately 1.930 million shares), ending the trading day in the 35,000 yen range for the first time in about a month since August 9th. Amid the yen's movement to around 141 yen to the dollar for the first time in about 8 months, selling pressure led to a wide range of stocks, especially export-related stocks. Furthermore, in the afternoon, concerns about performance led to renewed selling as the yen strengthened to around 140 yen to the dollar. The Nikkei average widened its decline towards the end of the afternoon session, temporarily dropping to 352.
No Data
No Data